HIPPOCRATES® project: A proof of concept of a collaborative program for hepatitis C virus micro-elimination in a prison setting

Table 1 Clinical characteristics are summarized

Prisoners characteristics	n (%)
Age
18-29 yr	7 (7.1)
30-39 yr	22 (22.5)
40-49 yr	47 (47.9)
50+ yr	22 (22.5)
Body mass index, kg/m2, mean	24.7 ± 3.2
HCV genotype
1a	53 (54.1)
1b	6 (6.1)
2	2 (2.0)
3	27 (27.6)
4	9 (9.2)
6	1 (1.0)
Tattooing
No	25 (25.5)
Made in prison	38 (38.8)
Made outside prison	68 (69.4)
Illicit drug use
No	5 (5.1)
Ever smoked heroin/marijuana only	93 (94.9)
Inject drugs	73 (74.5)
Smoker
No	9 (9.2)
Yes, < 10 cigarettes per day	27 (27,6)
Yes, > 10 cigarettes per day and < 20	31 (31,6)
Yes, > 20 cigarettes per day	31 (31.6)
Alcohol consumption
No	22 (22.4)
Yes, < 30 g day of alcohol	8 (8.2)
Yes, 30 g day of alcohol and < 60 g	13 (13.3)
Yes, 60 g day of alcohol	55 (56.1)
Medication
Opiate substitution therapy	26 (26.5)
Antidepressants	40 (40.8)
Benzodiazepines	69 (70.4)

HCV: Hepatitis C virus.

Table 2 Laboratory data in the beginning of the treatment

Laboratory data	Median (IQR)
Hemoglobin, g/dL	15.7 (14.9-16.0)
Leukocytes, × 109/L	7.9 (7.0-10.2)
Platelets, × 109/L	204.5 (175.8-238.8)
Albumin, g/dL	58.4 (55.0-61.1)
AST, U/L	36.0 (28.0-47.8)
ALT, U/L	47.0 (31.0-67.0)
GGT, U/L	41.5 (27.0-72.0)
Alkaline phosphatase, U/L	76.5 (65.5-94.5)
Total bilirubin, mg/dL	0.48 (0.32-0.6)
Total cholesterol, mg/dL	162.0 (142.0-200.0)
Alpha-fetoprotein, ng/mL	2.0 (1.4-3.5)
Creatinine, mg/dL	0.8 (0.7-0.9)
INR	1.0 (1.0-1.1)
Anti-HBc antibody+	41 (41.8%)
Anti-HBs antibody+	33 (33.7%)

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: γ-glutamyl transpeptidase; IQR: Interquartile range.

Table 3 Liver fibrosis according to liver elastography

Liver fibrosis according to liver elastography	n (%)
F0-F1	50 (51.0)
F2	26 (26.6)
F3	12 (12.2)
F4	10 (10.2)